![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1673585
¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : Á¦Ç° À¯Çüº°, À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)Multiplex Assay Market Size, Share, and Growth Analysis, By Product Type (Consumables, Instruments), By Type (Protein Multiplex Assays, Nucleic Acid Multiplex Assays), By Technology, By Application, By End-User, By Region - Industry Forecast 2025-2032 |
¸ÖƼÇ÷º½º ºÐ¼® ½ÃÀå ±Ô¸ð´Â 2023³â 37¾ï ´Þ·¯, 2024³â 40¾ï 5,000¸¸ ´Þ·¯¿¡¼ 2032³â¿¡´Â 83¾ï 7,000¸¸ ´Þ·¯·Î ¼ºÀåÇϰí, ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È 9.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°è ¸ÖƼÇ÷º½º ºÐ¼® ½ÃÀåÀº ¸¸¼º Áúȯ ¹× °¨¿°¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ±âÁ¸ ¹æ¹ý ´ëºñ ¸ÖƼÇ÷º½º ºÐ¼®ÀÇ ÀåÁ¡À¸·Î ÀÎÇØ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. dMMR °íÇü¾Ï ½Äº°À» À§ÇÑ Roche¿Í °°Àº FDA ½ÂÀΰú °°Àº µ¿¹Ý Áø´Ü ¾à¹°ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ ºÐ¾ßÀÇ ¹Ì·¡°¡ À¯¸ÁÇÏ´Ù´Â °ÍÀ» Áõ¸íÇÕ´Ï´Ù. ºñ¼Ò¼¼Æ÷Æó¾Ï°ú °°Àº ¾ÏÀÇ »ýÁ¸À²À» 3¹è±îÁö ³ôÀÏ ¼ö ÀÖ´Â Á¶±â Áø´ÜÀº ½ÃÀå È®´ë °¡´É¼ºÀ» ´õ¿í °Á¶Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À¸¶Ä¿ °ËÁõ ¹× ÀÚµ¿È ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é¼ ÇÏÀ̽º·çDz ºÐ¼®ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ½Å°æÅðÇ༺ Áúȯ µî ´Ù¾çÇÑ ¿ëµµ¿¡ ´ëÀÀÇÏ´Â ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ´Â Á¶±â ¹ß°ß°ú ÀÎÁöµµ¸¦ ³ôÀ̴µ¥ ¸Å¿ì Áß¿äÇϸç, ±Ã±ØÀûÀ¸·Î ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀÔ´Ï´Ù.
Multiplex Assay Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.05 billion in 2024 to USD 8.37 billion by 2032, growing at a CAGR of 9.5% during the forecast period (2025-2032).
The global multiplex assay market is experiencing significant growth driven by the increasing prevalence of chronic and infectious diseases and the advantages of multiplex assays over traditional methods. The rising utilization in companion diagnostics is particularly noteworthy, as evidenced by FDA approvals like Roche's for identifying dMMR solid tumors, indicating a promising future for this sector. Early disease diagnosis, which can triple survival rates for cancers such as non-small cell lung cancer, further emphasizes the market's expansion potential. Additionally, the validation of biomarkers and demand for automated systems bolster the need for high-throughput assays. With applications spanning cancer, autoimmune diseases, and neurodegenerative disorders, multiplex assays are pivotal in enhancing early detection and raising awareness, ultimately fueling market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Multiplex Assay market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Multiplex Assay Market Segments Analysis
Global Multiplex Assay Market is segmented by Product Type, Type, Technology, Application, End-User and region. Based on Product Type, the market is segmented into Consumables, Instruments and Software. Based on Type, the market is segmented into Protein Multiplex Assays, Nucleic Acid Multiplex Assays and Cell-based Multiplex Assays. Based on Technology, the market is segmented into Flow Cytometry, Fluorescence Detection, Luminescence, Multiplex Real-time PCR and Others. Based on Application, the market is segmented into Research & Development and Clinical Diagnostics. Based on End-User, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes, Reference Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Multiplex Assay Market
The increasing emphasis on personalized medicine is significantly fueling the growth of the multiplex assay market. These assays facilitate the simultaneous analysis of several biomarkers, which enhances patient stratification and leads to more tailored treatment options. By enabling healthcare providers to assess multiple health indicators at once, multiplex assays contribute to more accurate diagnoses and effective therapeutic strategies. This capability not only optimizes patient care but also supports the shift towards individualized therapies that cater to specific patient needs, thus reinforcing the demand for these advanced diagnostic tools in clinical settings.
Restraints in the Multiplex Assay Market
The multiplex assay market faces significant restraints primarily due to regulatory challenges that can hinder their widespread adoption. The complex nature of these assays necessitates obtaining regulatory approval, a process that is often time-consuming and financially burdensome. Such stringent requirements can deter manufacturers from developing and introducing new multiplex assays into the market, ultimately slowing innovation and limiting the availability of these advanced diagnostic tools. Consequently, the lengthy regulatory procedures may restrict market growth and access to potentially valuable multiplex assays that could significantly enhance diagnostic accuracy and efficiency across various medical applications.
Market Trends of the Multiplex Assay Market
The multiplex assay market is witnessing a significant trend towards the adoption of multiplex immunoassays, driven by their efficiency in measuring multiple protein targets within a single sample. This capability not only streamlines workflows but also enhances the accuracy and throughput of diagnostic testing, drug discovery, and biomarker identification processes. As healthcare continues to shift towards personalized medicine and more precise diagnostics, the demand for these assays is expected to grow steadily. Furthermore, advancements in technology that facilitate higher sensitivity and multiplexing capabilities are propelling market growth, positioning multiplex immunoassays as essential tools in clinical research and therapeutics.